Jolanda Howe Sells 4,732 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 4,732 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $435,249.36. Following the completion of the sale, the senior vice president owned 8,429 shares in the company, valued at $775,299.42. This represents a 35.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Jolanda Howe also recently made the following trade(s):

• On Monday, February 2nd, Jolanda Howe sold 968 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40.
• On Monday, January 26th, Jolanda Howe sold 842 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total transaction of $80,991.98.
• On Thursday, January 22nd, Jolanda Howe sold 926 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total transaction of $86,423.58.

Mirum Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ MIRM opened at $91.66 on Thursday. Mirum Pharmaceuticals, Inc. has a 12-month low of $36.88 and a 12-month high of $109.28. The company has a market capitalization of $5.53 billion, a PE ratio of -190.95 and a beta of 0.52. The company has a debt-to-equity ratio of 0.98, a current ratio of 2.67 and a quick ratio of 2.55. The firm’s 50-day moving average is $96.32 and its two-hundred day moving average is $81.08.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $148.93 million during the quarter, compared to analyst estimates of $141.78 million. During the same quarter in the prior year, the company earned $1.00 earnings per share. The firm’s revenue for the quarter was up 49.8% compared to the same quarter last year. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its stake in shares of Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the period. State Street Corp grew its position in shares of Mirum Pharmaceuticals by 59.2% in the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after purchasing an additional 797,088 shares during the period. Wellington Management Group LLP increased its stake in Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Mirum Pharmaceuticals by 709.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares during the last quarter. Finally, Voloridge Investment Management LLC lifted its position in Mirum Pharmaceuticals by 2,116.6% during the third quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares during the period.

Wall Street Analyst Weigh In

MIRM has been the subject of several recent research reports. Raymond James Financial reissued a “strong-buy” rating and set a $110.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen lowered Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Finally, Royal Bank Of Canada reduced their target price on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $117.00.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum announced completion of enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases — a material clinical milestone that keeps the program on track; topline readout is expected in Q4 2026 and could materially re‑rate the stock if positive. Mirum EXPAND Enrollment Milestone Highlights LIVMARLI Upside And Valuation Gap
• Neutral Sentiment: Institutional investors and analysts show continued interest: several large institutions increased positions in recent quarters and multiple sell‑side firms have raised price targets (consensus remains a “Moderate Buy” with a mid‑teens upside to consensus targets). This supports underlying demand but is not an immediate catalyst. MarketBeat Mirum Stock Page
• Negative Sentiment: Several insiders sold sizable blocks of stock on March 16 (CEO Christopher Peetz sold 40,985 shares for ~$3.77M; COO Peter Radovich sold 16,515 shares; CFO Eric Bjerkholt, SVP Jolanda Howe and others also sold) — all at an average price near $91.98. Large, clustered insider sales can be interpreted as profit‑taking and often weigh on sentiment even when executives retain meaningful stakes. SEC filing for the CEO sale: Peetz Form 4 — SVP sale coverage: InsiderTrades SVP Sale

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.